Literature DB >> 25965560

Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles.

Mike Mackness1, Bharti Mackness2.   

Abstract

Human PON1 is a HDL-associated lipolactonase capable of preventing LDL and cell membrane oxidation and is therefore considered to be atheroprotective. PON1 contributes to the antioxidative function of HDL and reductions in HDL-PON1 activity, prevalent in a wide variety of diseases with an inflammatory component, are believed to lead to dysfunctional HDL which can promote inflammation and atherosclerosis. However, PON1 is multifunctional and may contribute to other HDL functions such as in innate immunity, preventing infection by quorum sensing gram negative bacteria by destroying acyl lactone mediators of quorum sensing, and putative new roles in cancer development and the promotion of healthy ageing. In this review we explore the physiological roles of PON1 in disease development, as well as PON1 gene and protein structure, promiscuous activities and the roles of SNPs and ethnicity in determining PON1 activity.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Ageing; Atherosclerosis; HDL; Inflammation; LDL; Oxidation; Paraoxonase-1; Paraoxonases; Quorum quenching; Toxicology

Mesh:

Substances:

Year:  2015        PMID: 25965560      PMCID: PMC4458450          DOI: 10.1016/j.gene.2015.04.088

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  138 in total

1.  Study of factors influencing the decreased HDL associated PON1 activity with aging.

Authors:  Ildiko Seres; Gyorgy Paragh; Elaine Deschene; Tamas Fulop; Abdelouahed Khalil
Journal:  Exp Gerontol       Date:  2004-01       Impact factor: 4.032

Review 2.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

Authors:  D Steinberg; S Parthasarathy; T E Carew; J C Khoo; J L Witztum
Journal:  N Engl J Med       Date:  1989-04-06       Impact factor: 91.245

3.  Lack of association of PON polymorphisms with sporadic ALS in an Italian population.

Authors:  Claudia Ricci; Stefania Battistini; Lorena Cozzi; Michele Benigni; Paola Origone; Lorenzo Verriello; Christian Lunetta; Cristina Cereda; Pamela Milani; Giuseppe Greco; Maria Cristina Patrosso; Renzo Causarano; Claudia Caponnetto; Fabio Giannini; Massimo Corbo; Silvana Penco
Journal:  Neurobiol Aging       Date:  2010-04-09       Impact factor: 4.673

4.  Paraoxonase 1 genetic polymorphisms and susceptibility to breast cancer: a meta-analysis.

Authors:  Mostafa Saadat
Journal:  Cancer Epidemiol       Date:  2011-11-30       Impact factor: 2.984

Review 5.  Pharmacological and lifestyle factors modulating serum paraoxonase-1 activity.

Authors:  Jordi Camps; Judit Marsillach; Jorge Joven
Journal:  Mini Rev Med Chem       Date:  2009-07       Impact factor: 3.862

6.  Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties.

Authors:  Orit Rozenberg; Maayan Shiner; Michael Aviram; Tony Hayek
Journal:  Free Radic Biol Med       Date:  2008-03-08       Impact factor: 7.376

7.  Expression of human paraoxonase (PON1) during development.

Authors:  Toby B Cole; Rachel L Jampsa; Betsy J Walter; Tara L Arndt; Rebecca J Richter; Diana M Shih; Aaron Tward; Aldons J Lusis; Rhona M Jack; Lucio G Costa; Clement E Furlong
Journal:  Pharmacogenetics       Date:  2003-06

Review 8.  Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development.

Authors:  Michael Aviram; Mira Rosenblat
Journal:  Free Radic Biol Med       Date:  2004-11-01       Impact factor: 7.376

9.  Serum esterases. II. An enzyme hydrolysing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera.

Authors:  W N ALDRIDGE
Journal:  Biochem J       Date:  1953-01       Impact factor: 3.857

Review 10.  Paraoxonase: a multifaceted biomolecule.

Authors:  Binita Goswami; Devika Tayal; Nikhil Gupta; V Mallika
Journal:  Clin Chim Acta       Date:  2009-09-30       Impact factor: 3.786

View more
  78 in total

Review 1.  Organophosphate neurotoxicity to the voluntary motor system on the trail of environment-caused amyotrophic lateral sclerosis: the known, the misknown, and the unknown.

Authors:  Samantha J Merwin; Teresa Obis; Yanelli Nunez; Diane B Re
Journal:  Arch Toxicol       Date:  2017-01-09       Impact factor: 5.153

2.  Towards a new model and classification of mood disorders based on risk resilience, neuro-affective toxicity, staging, and phenome features using the nomothetic network psychiatry approach.

Authors:  Michael Maes; Juliana Brum Moraes; Kamila Landucci Bonifacio; Decio Sabbatini Barbosa; Heber Odebrecht Vargas; Ana Paula Michelin; Sandra Odebrecht Vargas Nunes
Journal:  Metab Brain Dis       Date:  2021-01-07       Impact factor: 3.584

Review 3.  Quorum quenching enzymes and their effects on virulence, biofilm, and microbiomes: a review of recent advances.

Authors:  Rakesh Sikdar; Mikael Elias
Journal:  Expert Rev Anti Infect Ther       Date:  2020-08-04       Impact factor: 5.091

Review 4.  Effects of Dietary Flavonoids on Reverse Cholesterol Transport, HDL Metabolism, and HDL Function.

Authors:  Courtney L Millar; Quinn Duclos; Christopher N Blesso
Journal:  Adv Nutr       Date:  2017-03-15       Impact factor: 8.701

5.  Generalized Anxiety Disorder (GAD) and Comorbid Major Depression with GAD Are Characterized by Enhanced Nitro-oxidative Stress, Increased Lipid Peroxidation, and Lowered Lipid-Associated Antioxidant Defenses.

Authors:  Michael Maes; Kamila Landucci Bonifacio; Nayara Rampazzo Morelli; Heber Odebrecht Vargas; Estefânia Gastaldello Moreira; Drozdstoy St Stoyanov; Décio Sabbatini Barbosa; André F Carvalho; Sandra Odebrecht Vargas Nunes
Journal:  Neurotox Res       Date:  2018-05-07       Impact factor: 3.911

6.  Downregulation of paraoxonase 3 contributes to aggressive human hepatocellular carcinoma progression and associates with poor prognosis.

Authors:  Yuepeng Jin; Qiang Li; Junjun Qiu; Xiufen Zhao; Chunxiao Zheng; Shixu Lv; Yongyu Bai; Yunfeng Shan; Le-Chi Ye
Journal:  Tumour Biol       Date:  2016-08-23

7.  Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol.

Authors:  Eline H van den Berg; Eke G Gruppen; Richard W James; Stephan J L Bakker; Robin P F Dullaart
Journal:  J Lipid Res       Date:  2018-11-19       Impact factor: 5.922

8.  Higher serum lipids and oxidative stress in patients with normal tension glaucoma, but not pseudoexfoliative glaucoma.

Authors:  Necat Yilmaz; Deniz Turgut Coban; Asli Bayindir; Muhammet Kazım Erol; Hamit Yasar Ellidag; Ozlem Giray; Suha Sayrac; Seckin Ozgur Tekeli; Esin Eren
Journal:  Bosn J Basic Med Sci       Date:  2016-01-01       Impact factor: 3.363

9.  Serum paraoxonase 1 activity in cats: analytical validation, reference intervals, and correlation with serum amyloid A and alpha-1-acid glycoprotein.

Authors:  Gabriele Rossi; Sara Meazzi; Alessia Giordano; Saverio Paltrinieri
Journal:  J Vet Diagn Invest       Date:  2020-08-17       Impact factor: 1.279

10.  Identification of Critical Paraoxonase 1 Residues Involved in High Density Lipoprotein Interaction.

Authors:  Xiaodong Gu; Ying Huang; Bruce S Levison; Gary Gerstenecker; Anthony J DiDonato; Leah B Hazen; Joonsue Lee; Valentin Gogonea; Joseph A DiDonato; Stanley L Hazen
Journal:  J Biol Chem       Date:  2015-11-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.